In last trading session, Iterum Therapeutics plc (NASDAQ:ITRM) saw 1.13 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $0.39 trading at -$0.02 or -5.54% at ring of the bell on the day assigns it a market valuation of $71.61M. That closing price of ITRM’s stock is at a discount of -666.67% from its 52-week high price of $2.99 and is indicating a premium of 2.56% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.22 million shares which gives us an average trading volume of 4.55 million if we extend that period to 3-months.
Iterum Therapeutics plc (NASDAQ:ITRM) trade information
Upright in the red during last session for losing -5.54%, in the last five days ITRM remained trading in the red while hitting it’s week-highest on Wednesday, 01/12/22 when the stock touched $0.39 price level, adding 10.34% to its value on the day. Iterum Therapeutics plc’s shares saw a change of -0.43% in year-to-date performance and have moved -4.85% in past 5-day. Iterum Therapeutics plc (NASDAQ:ITRM) showed a performance of -15.18% in past 30-days. Number of shares sold short was 4.19 million shares which calculate 1.27 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $1.00 to the stock, which implies a rise of 61.0% to its current value. Analysts have been projecting $1.00 as a low price target for the stock while placing it at a high target of $1.00. It follows that stock’s current price would drop -156.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -156.41% for stock’s current value.
Iterum Therapeutics plc (ITRM) estimates and forecasts
Statistics highlight that Iterum Therapeutics plc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -66.37% of value to its shares in past 6 months, showing an annual growth rate of 78.34% while that of industry is 16.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 85.20% in the current quarter and calculating 93.80% increase in the next quarter.
Iterum Therapeutics plc is more likely to be releasing its next quarterly report between March 10 and March 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Iterum Therapeutics plc (NASDAQ:ITRM)’s Major holders
Insiders are in possession of 0.62% of company’s total shares while institution are holding 4.24 percent of that, with stock having share float percentage of 4.27%. Investors also watch the number of corporate investors in a company very closely, which is 4.24% institutions for Iterum Therapeutics plc that are currently holding shares of the company. Canaan Partners X LLC is the top institutional holder at ITRM for having 1.73 million shares of worth $0.97 million. And as of Sep 29, 2021, it was holding 0.95% of the company’s outstanding shares.
The second largest institutional holder is New Leaf Venture Partners, L.l.c., which was holding about 1.46 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 0.80% of outstanding shares, having a total worth of $0.81 million.
On the other hand, Legg Mason Global Asset Mgt Tr-QS US Small Cap Equity and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 0.38 million shares of worth $0.21 million or 0.21% of the total outstanding shares. The later fund manager was in possession of 33113.0 shares on Oct 30, 2021, making its stake of worth around $17682.0 in the company or a holder of 0.02% of company’s stock.